Italia markets open in 4 hours 16 minutes

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
83,13+2,45 (+3,04%)
Alla chiusura: 04:00PM EST
83,00 -0,13 (-0,16%)
Dopo ore: 05:14PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente80,68
Aperto80,28
Denaro81,80 x 900
Lettera83,35 x 800
Min-Max giorno80,20 - 83,34
Intervallo di 52 settimane64,32 - 84,86
Volume1.651.710
Media Volume1.408.717
Capitalizzazione18,494B
Beta (5 anni mensile)0,69
Rapporto PE (ttm)21,21
EPS (ttm)3,92
Prossima data utili06 feb 2023 - 10 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A87,00
  • GlobeNewswire

    Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil

    MONTREAL, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for tafasitamab in combination with lenalidomide to ANVISA, the Brazilian health regulatory agency, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for auto

  • GlobeNewswire

    Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer

    Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitorsCHICAGO and FORT WORTH, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient on a Phase 2 study of elraglusib (9-ING-41) plus retifanlimab combined with gemcitabine/nab-paclitaxel fo

  • GlobeNewswire

    Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a rang